MY193257A - Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same - Google Patents

Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same

Info

Publication number
MY193257A
MY193257A MYPI2017703532A MYPI2017703532A MY193257A MY 193257 A MY193257 A MY 193257A MY PI2017703532 A MYPI2017703532 A MY PI2017703532A MY PI2017703532 A MYPI2017703532 A MY PI2017703532A MY 193257 A MY193257 A MY 193257A
Authority
MY
Malaysia
Prior art keywords
pharmaceutically acceptable
pyrrole derivatives
methoxy pyrrole
acceptable salts
pharmaceutical composition
Prior art date
Application number
MYPI2017703532A
Other languages
English (en)
Inventor
Chun Ho Lee
Seung Chul Lee
Yeon Im Lee
Deok Ki Eom
Mi Ryeong Han
Eun Ji Koh
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MY193257A publication Critical patent/MY193257A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MYPI2017703532A 2015-04-27 2016-04-27 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same MY193257A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150058712 2015-04-27
KR1020160013588A KR101613245B1 (ko) 2015-04-27 2016-02-03 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
PCT/KR2016/004411 WO2016175555A2 (fr) 2015-04-27 2016-04-27 Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant

Publications (1)

Publication Number Publication Date
MY193257A true MY193257A (en) 2022-09-28

Family

ID=55916928

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017703532A MY193257A (en) 2015-04-27 2016-04-27 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same

Country Status (29)

Country Link
US (1) US10100010B1 (fr)
EP (1) EP3197867B1 (fr)
JP (1) JP6244498B1 (fr)
KR (2) KR101613245B1 (fr)
CN (1) CN107001263B (fr)
AU (1) AU2016255308B2 (fr)
CA (1) CA2977750C (fr)
CL (1) CL2017002571A1 (fr)
CO (1) CO2017010539A2 (fr)
DO (2) DOP2017000230A (fr)
EC (1) ECSP17071036A (fr)
ES (1) ES2703709T3 (fr)
HR (1) HRP20182066T1 (fr)
HU (1) HUE042449T2 (fr)
MA (1) MA40887B1 (fr)
MX (1) MX2017012507A (fr)
MY (1) MY193257A (fr)
NZ (1) NZ734896A (fr)
PE (1) PE20180022A1 (fr)
PH (1) PH12017501755B1 (fr)
PL (1) PL3197867T3 (fr)
PT (1) PT3197867T (fr)
RS (1) RS58076B1 (fr)
RU (1) RU2663895C1 (fr)
SA (1) SA517390127B1 (fr)
SG (1) SG11201706877RA (fr)
SI (1) SI3197867T1 (fr)
TN (1) TN2017000424A1 (fr)
WO (1) WO2016175555A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
WO2017164575A1 (fr) * 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
WO2020060213A1 (fr) 2018-09-19 2020-03-26 주식회사 대웅제약 Procédé de production d'un dérivé de 4-méthoxy pyrrole
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
KR102570011B1 (ko) * 2019-12-18 2023-08-23 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물
CN115884968B (zh) * 2020-06-17 2024-06-21 日东制药株式会社 新型酸分泌抑制剂及其用途
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
WO2022051979A1 (fr) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 Procédé de préparation d'intermédiaire de bloqueur compétitif d'ions de potassium
DK4245298T3 (en) * 2020-12-18 2026-03-30 Daewoong Pharmaceutical Co Ltd Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin
JP7802829B2 (ja) * 2021-05-26 2026-01-20 デウン ファーマシューティカル カンパニー リミテッド 1-(5-(2,4-ジフルオロフェニル)-1-((3-フルオロフェニル)スルホニル)-4-メトキシ-1h-ピロール-3-イル)-n-メチルメタンアミンを含む新規な注射用製剤
TN2023000270A1 (en) * 2021-05-26 2025-07-02 Daewoong Pharmaceutical Co Ltd Medicine container containing liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
TWI884372B (zh) * 2021-05-26 2025-05-21 南韓商大熊製藥股份有限公司 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器
KR102556500B1 (ko) * 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물
KR20240119083A (ko) * 2021-12-15 2024-08-06 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US20240415808A1 (en) * 2021-12-15 2024-12-19 Daewoong Pharmaceutical Co., Ltd. Dosage Regimen for Fexuprazan Injection Composition
CN118401510A (zh) * 2021-12-15 2024-07-26 日东制药株式会社 1-磺酰基吡咯衍生物的新颖盐类、其制备方法及包含其的药物组合物
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
WO2023211843A1 (fr) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Bloqueurs d'acide compétitif pour le potassium pour le traitement d'états hypersécrétoires pathologiques
WO2023229323A1 (fr) * 2022-05-23 2023-11-30 일동제약(주) Procédé de préparation d'un dérivé de 6-méthoxypyridin-3-yle
CN119365448A (zh) * 2022-05-23 2025-01-24 日东制药株式会社 一种6-甲氧基吡啶-3-基衍生物的制备方法
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
CN115557876A (zh) * 2022-10-26 2023-01-03 四川国康药业有限公司 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途
KR102938657B1 (ko) 2023-02-15 2026-03-12 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
KR20250124776A (ko) * 2024-02-13 2025-08-20 유노비아 주식회사 6-메톡시피리딘-3-일 유도체를 포함하는 위장관 질환의 치료 방법
KR20260020368A (ko) * 2024-08-02 2026-02-11 일양약품주식회사 4-사이클로프로필 피롤 유도체 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466375A1 (fr) 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Composes heteroaryles substitues azabicycliques pour le traitement de maladies
EP1545515A1 (fr) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
CN101006082B (zh) 2004-08-23 2010-09-29 伊莱利利公司 组胺h3受体药剂、制备方法和治疗用途
KR100958829B1 (ko) 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
KR101178747B1 (ko) 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
CN102114244A (zh) 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
PE20070540A1 (es) * 2005-08-30 2007-06-26 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
DE102005041246A1 (de) 2005-08-31 2007-03-08 Basf Coatings Ag Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung
KR101088247B1 (ko) 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
EA014915B1 (ru) 2006-05-04 2011-02-28 Солвей Фармасьютикалс Б.В. Мускариновые агонисты для лечения расстройств контроля над побуждениями
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2008131779A1 (fr) 2007-04-26 2008-11-06 H. Lundbeck A/S Dérivés d'isoquinolinone utilisés en tant qu'antagonistes de nk3
CA2796756A1 (fr) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines substituees destinees au traitement de troubles du systeme nerveux central
CA2891523A1 (fr) * 2012-11-19 2014-05-22 Jiangsu Hansoh Pharmaceutical Co., Ltd. Derive pyrrole sulfonamide, procede de preparation et application medicale associes
AU2014240139A1 (en) 2013-03-15 2015-09-17 Acadia Pharmaceuticals Inc. Muscarinic agonists
ITBS20130175A1 (it) 2013-11-22 2015-05-23 Ind Saleri Italo Spa Gruppo pompa di raffreddamento regolabile con girante regolabile
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
CN104447191B (zh) 2014-10-30 2016-03-23 绵阳达高特新材料有限公司 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途

Also Published As

Publication number Publication date
KR101613245B1 (ko) 2016-04-18
EP3197867B1 (fr) 2018-11-14
PL3197867T3 (pl) 2019-03-29
CN107001263A (zh) 2017-08-01
WO2016175555A8 (fr) 2017-09-08
MA40887B1 (fr) 2019-01-31
EP3197867A4 (fr) 2017-09-06
CL2017002571A1 (es) 2018-03-16
DOP2017000230A (es) 2017-10-31
ECSP17071036A (es) 2017-12-01
DOP2021000213A (es) 2021-11-15
TN2017000424A1 (en) 2019-04-12
US10100010B1 (en) 2018-10-16
MA40887A (fr) 2017-08-02
SG11201706877RA (en) 2017-09-28
AU2016255308B2 (en) 2017-08-31
CO2017010539A2 (es) 2018-01-31
JP6244498B1 (ja) 2017-12-06
RU2663895C1 (ru) 2018-08-13
PE20180022A1 (es) 2018-01-09
MX2017012507A (es) 2018-01-30
CA2977750A1 (fr) 2016-11-03
KR101818704B1 (ko) 2018-02-21
AU2016255308A1 (en) 2017-05-18
JP2017538716A (ja) 2017-12-28
SI3197867T1 (sl) 2019-02-28
HUE042449T2 (hu) 2019-06-28
BR112017020056A2 (pt) 2018-06-05
CA2977750C (fr) 2019-06-11
NZ734896A (en) 2019-07-26
PT3197867T (pt) 2019-01-10
SA517390127B1 (ar) 2020-11-08
PH12017501755B1 (en) 2022-11-16
HRP20182066T1 (hr) 2019-02-08
KR20160127646A (ko) 2016-11-04
EP3197867A2 (fr) 2017-08-02
CN107001263B (zh) 2018-10-19
RS58076B1 (sr) 2019-02-28
PH12017501755A1 (en) 2018-04-02
ES2703709T3 (es) 2019-03-12
WO2016175555A2 (fr) 2016-11-03
WO2016175555A3 (fr) 2017-02-16

Similar Documents

Publication Publication Date Title
MY193257A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
WO2015200481A8 (fr) Inhibiteurs de mnk et procédés associés
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EP4656249A3 (fr) Dérivés de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de kinase
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
SG11201900298RA (en) Heterocyclic compound used as fgfr inhibitor
MX379775B (es) Nueva sal de adición ácida de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina.
HK1255500A1 (zh) 氧固醇及其使用方法
EP4582424A3 (fr) Dérivé de 1,2-naphtoquinone et son procédé de préparation
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2015199418A3 (fr) Nouveau composé hétérocyclique
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
WO2019036417A3 (fr) Inhibition de ngly1 pour le traitement du cancer
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
WO2018080215A8 (fr) Dérivé d'indole 3-amino alkylé, procédé de préparation et composition pharmaceutique associés
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
HK1231074A1 (en) Neprilysin inhibitors
HK1217191A1 (zh) 治療性化合物和其用途
TH148359A (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
MX354999B (es) Composicion con un inhibidor de la bomba de protones y un antagonista h2.